Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Epigenetics of Bladder Cancer Evolution.

Project description

Uncovering bladder cancer biological mechanisms

Tumour evolution, characterised by genetic and epigenetic changes among diverse cancer cell clones, plays a role in disease progression and therapy resistance. With support from the Marie Skłodowska-Curie Actions programme, the Epi-BCE project will investigate the biological mechanisms underlying bladder cancer, focusing on how alterations in chromatin regulation contribute to advanced disease and treatment resistance. The project will use a carcinogen-based mouse model that replicates human bladder cancer progression, from early stages to advanced, therapy-resistant disease. It will conduct transcriptomics and epigenomics analyses at both bulk and single-cell levels throughout disease progression. It will use genetically engineered mice with ablated chromatin regulation proteins to identify key mechanisms driving bladder cancer evolution. Ultimately, the project aims to improve treatment strategies.

Objective

Cancer is one of the leading causes of death worldwide and its management remains challenging. Tumor evolution, the process of genetic and epigenetic divergence and selection of cancer cell clones in a heterogeneous tumor, is a key aspect of disease progression and therapy resistance. The main goal of this proposal is to expand our understanding of the biological mechanisms involved in these processes. So far, the role of chromatin regulation and epigenetics in tumor evolution remains poorly characterized and understood. This is particularly relevant in bladder cancer where mutations in chromatin regulation are very frequent and are associated with advanced and therapy resistant disease.
Epi-BCE will advance the state-of-the-art through the discovery of epigenetic mechanisms that drive bladder cancer progression and chemoresistance in cell subpopulations, and tumors with chromatin deregulation. Specifically, I will utilize a carcinogen-based mouse model of bladder cancer that recapitulates human cancer stages from early to advanced and therapy resistant disease. I will perform transcriptomics and epigenomics at bulk and single-cell level at stages of disease progression. In addition, I will employ genetically engineered mice with ablation of chromatin regulation proteins, integrative computational analysis and functional genetic experiments to identify key mechanisms.
Epi-BCE will be a platform for professional growth. I will receive technical training in experimental mouse models, bioinformatics, and 3D genomics through a secondment. I will engage in new professional networks and acquire transferable skills. Grantsmanship activities will support the fellow towards a path to independence.
Overall, the proposed experiments will yield scientific knowledge and reusable datasets on cancer biology. These outcomes will promote and accelerate future research on cancer management and therapeutics.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-TMA-MSCA-PF-EF - HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-MSCA-2024-PF-01

See all projects funded under this call

Coordinator

IDRYMA IATROVIOLOGIKON EREUNON AKADEMIAS ATHINON
Net EU contribution
€ 197 263,68
Address
SORANOU EFESIOU 4
115 27 ATHINA
Greece
Region
Αττική Aττική Κεντρικός Τομέας Αθηνών
Activity type
Research Organisations
Links
Total cost
No data

Partners (1)